Clinical trial
Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA…
NCT00382616 · Tel-Aviv Sourasky Medical Center, Other · Completed
Key facts
| NCT number | NCT00382616 |
|---|---|
| Title | Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD |
| Official title | Studying the Effects of Phosphatidylserine Enriched With Omega-3 Fatty Acids on Symptoms of Attention-Deficit/Hyperactivity Disorder in Children |
| Lead sponsor | Tel-Aviv Sourasky Medical Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention-Deficit/Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Phosphatidylserine-Omega3 |
| Enrollment | 90 |
| Start date | Jul 1, 2004 |
| Completion | Jan 1, 2005 |
| First posted | Sep 29, 2006 |
| Last update posted | Nov 7, 2006 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: